Last reviewed · How we verify
NCT03926832: SARCOIDOSAS
Prevalence of Obstructive Sleep Apnea Syndrome in Sarcoidosis and Impact of CPAP Treatment on Associated Fatigue Status
NA trial testing Continuous Positive Airway Pressure (CPAP) in Sarcoidosis in 68 participants. Completed in 30 July 2019.
15 May 2019
Quick facts
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 68 |
| Start date | 27 April 2019 |
| Primary completion | 15 May 2019 |
| Estimated completion | 30 July 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Continuous Positive Airway Pressure (CPAP)
Conditions studied
- Sarcoidosis — all drugs for Sarcoidosis →
- Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →
- Fatigue — all drugs for Fatigue →
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
Adults 18 to 85, any sex, with Sarcoidosis or Sleep Apnea, Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sarcoidosis is a multisystemic granulomatous disease that affects individuals worldwide without known pathogenesis, and the role of comorbidities has not been fully assessed in the scientific literature. An increased incidence of Obstructive Sleep Apnea Syndrome (OSAS) has been described in Sarcoidosis although this association has not been explained yet and no data is available about the effect of treatment with Continuous Positive Airway Pressure (CPAP) in Sarcoidosis. Also, patients affected by Sarcoidosis usually experience a state of physical and mental weariness called fatigue and reported in approximately 60-80% sarcoid patients and thought to be a consequence of inflammatory mediators but the high prevalence of OSAS could be a remarkable bias in clinical evaluation because fatigue is also strongly associated with sleep disorders. Thus, there is a real need for assessing not only the real prevalence of OSAS in Sarcoidosis but also the effect of CPAP treatment on fatigue status experienced by sarcoidotic patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue.
Mari PV, Pasciuto G, Siciliano M, Simonetti J, et al · · 2020 · cited 13× · PMID 33093780 · DOI 10.36141/svdld.v37i2.9169
Verify or expand the search:
- PubMed search for NCT03926832
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous Positive Airway Pressure (CPAP)
Trials testing the same drug.
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07176117 — Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants · NA · not yet recruiting
- NCT07358429 — CPAP Therapy and Atrial Fibrillation Recurrence in OSA · active not recruiting
- NCT06292325 — Psychological Aspects in OSA · completed
- NCT05475119 — Effect of High Flow Nasal Cannula Versus Continues Positive Airway Pressure in Adults With Obstructive Sleep Apnea · NA · unknown
Other recruiting trials for Sarcoidosis
Currently open trials in the same condition.
- NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
- NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
- NCT07384897 — Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease · NA · recruiting
- NCT06636487 — Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD · NA · active not recruiting
- NCT06576505 — Immunological Mechanisms in Sarcoidosis · recruiting
Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials
Trials by the same sponsor.
- NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
- NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
- NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
- NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
- NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03926832 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Last refreshed: 23 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03926832.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing